AIM: To evaluate cladribine [2-chlorodeoxyadenosine (2-CdA)] therapy in refractory celiac disease (RCD) II. METHODS: An open-label cohort-study of RCD II patients treated with 2-CdA was performed between 2000 and 2010. Survival rate, enteropathy associated T-cell lymphoma (EATL) occurrence, clinical course, and histological and immunological response rates were evaluated. RESULTS: Overall, 32 patients were included with a median follow-up of 31 mo. Eighteen patients responded well to 2-CdA. Patients responsive to 2-CdA had a statistically significant increased survival compared to those who were unresponsive. The overall 3- and 5-year survival was 83% in the responder and 63% and 22% in the non-responder group, respectively. The overall 2-year clinical, histological and immunological response rates were 81%, 47% and 41%, respectively. Progression into EATL was reported in 16%, all of these patients died. CONCLUSION: Treatment of RCD II with 2-CdA holds promise, showing excellent clinical and histological response rates, and probably less frequent transition into EATL.
AIM: To evaluate cladribine [2-chlorodeoxyadenosine (2-CdA)] therapy in refractory celiac disease (RCD) II. METHODS: An open-label cohort-study of RCD IIpatients treated with 2-CdA was performed between 2000 and 2010. Survival rate, enteropathy associated T-cell lymphoma (EATL) occurrence, clinical course, and histological and immunological response rates were evaluated. RESULTS: Overall, 32 patients were included with a median follow-up of 31 mo. Eighteen patients responded well to 2-CdA. Patients responsive to 2-CdA had a statistically significant increased survival compared to those who were unresponsive. The overall 3- and 5-year survival was 83% in the responder and 63% and 22% in the non-responder group, respectively. The overall 2-year clinical, histological and immunological response rates were 81%, 47% and 41%, respectively. Progression into EATL was reported in 16%, all of these patients died. CONCLUSION: Treatment of RCD II with 2-CdA holds promise, showing excellent clinical and histological response rates, and probably less frequent transition into EATL.
Authors: Wieke H M Verbeek; Marco W J Schreurs; Otto J Visser; B Mary E von Blomberg; Abdulbaqi Al-Toma; Chris J J Mulder Journal: Expert Rev Clin Immunol Date: 2008-03 Impact factor: 4.473
Authors: Muhammed Hadithi; Maarten Mallant; Joost Oudejans; Jan-Hein T M van Waesberghe; Chris J Mulder; Emile F I Comans Journal: J Nucl Med Date: 2006-10 Impact factor: 10.057
Authors: Muhammed Hadithi; Abdulbaqi Al-toma; Joost Oudejans; Adriaan A van Bodegraven; Chris J Mulder; Maarten Jacobs Journal: Am J Gastroenterol Date: 2007-03-22 Impact factor: 10.864
Authors: W H M Verbeek; B M E von Blomberg; V M H Coupe; S Daum; C J J Mulder; M W J Schreurs Journal: Cytometry B Clin Cytom Date: 2009-11 Impact factor: 3.058
Authors: Wieke H M Verbeek; Marije S Goerres; B Mary E von Blomberg; Joost J Oudejans; Petra E T Scholten; Muhammed Hadithi; Abdul Al-Toma; Marco W J Schreurs; Chris J J Mulder Journal: Clin Immunol Date: 2007-11-26 Impact factor: 3.969
Authors: M S Goerres; J W R Meijer; P J Wahab; J A M Kerckhaert; P J T A Groenen; J H J M Van Krieken; C J J Mulder Journal: Aliment Pharmacol Ther Date: 2003-09-01 Impact factor: 8.171
Authors: R L J van Wanrooij; D M J Müller; E A Neefjes-Borst; J Meijer; L G Koudstaal; D A M Heideman; H J Bontkes; B M E von Blomberg; G Bouma; C J J Mulder Journal: J Clin Immunol Date: 2014-07-27 Impact factor: 8.317
Authors: P Nijeboer; Rlj van Wanrooij; T van Gils; N J Wierdsma; G J Tack; B I Witte; H J Bontkes; O Visser; Cjj Mulder; G Bouma Journal: United European Gastroenterol J Date: 2016-06-23 Impact factor: 4.623
Authors: Tom van Gils; Petula Nijeboer; Jan Hein Tm van Waesberghe; Veerle Mh Coupé; Kiki Janssen; Jessy A Zegers; Shaikh A Nurmohamed; Georg Kraal; Sabine Ci Jiskoot; Gerd Bouma; Chris Jj Mulder Journal: United European Gastroenterol J Date: 2016-08-17 Impact factor: 4.623
Authors: Elisabeth Megan Rose Baggus; Marios Hadjivassiliou; Simon Cross; Hugo Penny; Heidi Urwin; Sarah Watson; Jeremy Mark Woodward; David S Sanders Journal: Frontline Gastroenterol Date: 2019-08-08
Authors: Alberto Rubio-Tapia; Ivor D Hill; Ciarán P Kelly; Audrey H Calderwood; Joseph A Murray Journal: Am J Gastroenterol Date: 2013-04-23 Impact factor: 10.864
Authors: Jolanda M W van de Water; Petula Nijeboer; Laura R de Baaij; Jessy Zegers; Gerd Bouma; Otto J Visser; Donald L van der Peet; Chris J J Mulder; Wilhelmus J H J Meijerink Journal: World J Gastroenterol Date: 2015-11-21 Impact factor: 5.742
Authors: Tom van Gils; Petula Nijeboer; Roy L van Wanrooij; Gerd Bouma; Chris J J Mulder Journal: Nat Rev Gastroenterol Hepatol Date: 2015-09-08 Impact factor: 46.802